赛隆药业(002898) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥54,086,779.12, a decrease of 22.16% compared to ¥69,484,400.80 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥1,038,505.28, representing a decline of 163.94% from a profit of ¥1,624,090.66 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0059, down 164.13% from ¥0.0092 in the previous year[5] - The net profit for the current period is -1,038,505.28, compared to a net profit of 1,624,090.66 in the previous period, indicating a significant decline[18] - Operating profit for the current period is -1,073,070.53, down from 2,177,192.65 in the previous period[18] Cash Flow and Liquidity - The net cash flow from operating activities improved by 26.09%, with a net outflow of ¥12,886,962.58 compared to ¥17,436,292.79 in the same period last year[5] - The company recorded a net cash outflow from investing activities of ¥1,990,177.26, a decline of 267.66% compared to a net inflow of ¥1,187,045.07 in the previous year[8] - The cash and cash equivalents have decreased to ¥32,973,514.85 from ¥48,843,383.16, representing a decline of approximately 32.5%[13] - Cash and cash equivalents at the end of the period decreased to 32,097,514.85 from 54,532,212.02 in the previous period[20] - The company received cash inflow from financing activities of 36,700,000.00, compared to 20,000,000.00 in the previous period, indicating increased borrowing[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥806,068,851.46, a slight decrease of 0.27% from ¥808,223,377.29 at the end of the previous year[5] - The total current assets have increased slightly to ¥251,821,316.13 from ¥249,830,978.43, showing a growth of about 0.8%[14] - The total liabilities have decreased to ¥307,548,596.99 from ¥308,946,095.60, reflecting a decline of approximately 0.5%[15] - The total assets amount to ¥806,068,851.46, which is a slight decrease from ¥808,223,377.29, indicating a reduction of about 0.3%[15] Expenses - The company's sales expenses increased by 70.74% to ¥9,311,231.72, attributed to increased sales activities during the period[8] - Research and development expenses increased to 6,059,564.36 from 5,344,923.89, reflecting a focus on innovation[18] - The company incurred a financial expense of 1,721,374.90, up from 1,460,757.48, primarily due to interest expenses[18] Accounts Receivable and Inventory - The accounts receivable have increased to ¥84,401,321.66 from ¥67,046,975.03, marking an increase of about 25.9%[13] - The inventory has decreased to ¥89,391,143.96 from ¥94,077,645.27, indicating a reduction of approximately 5.0%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,462, with the largest shareholder holding 51.15% of the shares[10]